Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial

被引：0
|
作者：
Kim, H. [1 ]
Park, S. [2 ]
Kim, T. M. [3 ]
Han, J-Y. [4 ]
Lee, G-W. [5 ,6 ]
Shim, B. Y. [7 ]
Lee, Y-G. [8 ]
Kim, S-W. [9 ]
Ock, C-Y. [10 ]
Hwang, S. [11 ]
Lee, Y. [12 ]
Kim, R. [13 ]
Jung, H. A. [14 ]
Sun, J-M. [15 ]
Lee, S-H. [16 ]
Ahn, J. S. [15 ]
Ahn, M-J. [17 ]
机构：
[1] Samsung Med Ctr SMC, Hematooncol, Seoul, South Korea
[2] Samsung Med Ctr SMC, Hematol & Med Oncol, Seoul, South Korea
[3] Seoul Natl Univ, Internal Med Dept, Coll Med, Yeongeon Med Campus, Seoul, South Korea
[4] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Ctr Lung Canc, Goyang, South Korea
[5] Gyeongsang Natl Univ Hosp, Internal Med Dept, Jinju, South Korea
[6] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea
[7] Catholic Univ Korea, Dept Internal Med, St Vincents Hosp, Suwon, South Korea
[8] Kangbuk Samsung Hosp, Samsung Med Ctr SMC, Dept Internal Med, Seoul, South Korea
[9] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea
[10] Lunit Inc, Med Affairs, Oncol Grp, Seoul, South Korea
[11] Lunit, Med Affairs, Oncol Grp, Seoul, South Korea
[12] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea
[13] Inocras, Oncol Dept, San Diego, CA USA
[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Hematol Oncol,Dept Med, Seoul, South Korea
[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Med, Seoul, South Korea
[16] Samsung Med Ctr SMC, Med Oncol, Seoul, South Korea
[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Hematol Oncol Dept, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631P
引用
收藏
页码：S1636 / S1636
页数：1
相关论文
共 50 条
  • [31] Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
    Passaro, A.
    Cho, B. C.
    Wang, Y.
    Melosky, B.
    Califano, R.
    Lee, S-H.
    Girard, N.
    Reckamp, K. L.
    Takahashi, T.
    Felip, E.
    Gentzler, R. D.
    Popat, S.
    William, W. Nassib, Jr.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Garcia-Campelo, M. R.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1307 - S1307
  • [32] Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis
    Peng, Juan
    Xu, Huiling
    Liu, Qiao
    PLOS ONE, 2024, 19 (10):
  • [33] Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result
    Hong, Yaping
    Zhuang, Wu
    Lai, Jinhuo
    Xu, Haipeng
    He, Yueming
    Lin, Jinlan
    Shi, Qin
    Chen, Shengjia
    Huang, Zhangzhou
    Chen, Shijie
    Lu, Dongzhu
    Lin, Gen
    Huang, Yunjian
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [34] Phase II randomized trial of carboplatin plus pemetrexed plus bevacizumab, plus /- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.
    Bodor, Joseph Nicholas
    Patel, Jyoti D.
    Ross, Eric A.
    Litwin, Samuel
    Clapper, Margie
    Levy, Benjamin Philip
    Wakelee, Heather A.
    Borghaei, Hossein
    Treat, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC
    Heymach, John V.
    Yu, Helena A.
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel S. W.
    Wei, Li
    Wacheck, Volker
    Nishio, Makoto
    FUTURE ONCOLOGY, 2025, 21 (05) : 549 - 556
  • [36] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
  • [37] Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
    Wu, Shang-Gin
    Ho, Chao-Chi
    Yang, James Chih-Hsin
    Yu, Shu-Han
    Lin, Yen-Feng
    Lin, Shu-Chin
    Liao, Bin-Chi
    Yang, Ching-Yao
    Lin, Yen-Ting
    Yu, Chong-Jen
    Chuang, Ya-Ting
    Liao, Wei-Yu
    Yap, Kah Yi
    Kou, Weng Si
    Shih, Jin-Yuan
    CLINICAL AND TRANSLATIONAL MEDICINE, 2025, 15 (01):
  • [38] VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
    Lu, S.
    Wu, L.
    Jian, H.
    Cheng, Y.
    Wang, Q.
    Fang, J.
    Wang, Z.
    Hu, Y.
    Sun, M.
    Han, L.
    Miao, L.
    Ding, C.
    Cui, J.
    Li, B.
    Li, X.
    Wang, K.
    Cang, S.
    Pan, Y.
    Ye, F.
    Liu, A.
    ANNALS OF ONCOLOGY, 2022, 33 (01) : 112 - 113
  • [39] Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC
    Argiles, G.
    Bendell, J.
    Kim, T.
    Wongchenko, M.
    DuPree, K.
    Mahrus, S.
    Qu, X.
    Shi, Y.
    Uyei, A.
    Roberts, L.
    Yan, Y.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S229 - S229
  • [40] Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab-interim analysis of the FAB-HCC phase II pilot study
    Pomej, Katharina
    Frick, Adrian
    Scheiner, Bernhard
    Balcar, Lorenz
    Pajancic, Larissa
    Klotz, Anton
    Regnat, Katharina
    Zinober, Kerstin
    Trauner, Michael
    Tamandl, Dietmar
    Gasche, Christoph
    Pinter, Matthias
    JOURNAL OF HEPATOLOGY, 2024, 80 : S436 - S437
12345